A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors by Hieronymus, Fredrik et al.
Chalmers Publication Library
A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of
action for the antidepressant effect of three selective serotonin reuptake inhibitors
This document has been downloaded from Chalmers Publication Library (CPL). It is the author´s
version of a work that was accepted for publication in:
Translational Psychiatry (ISSN: 2158-3188)
Citation for the published paper:
Hieronymus, F. ; Nilsson, S. ; Eriksson, E. (2016) "A mega-analysis of fixed-dose trials
reveals dose-dependency and a rapid onset of action for the antidepressant effect of three
selective serotonin reuptake inhibitors". Translational Psychiatry, vol. 6(6),  pp. artikel nr
e834.
http://dx.doi.org/10.1038/tp.2016.104
Downloaded from: http://publications.lib.chalmers.se/publication/243394
Notice: Changes introduced as a result of publishing processes such as copy-editing and
formatting may not be reflected in this document. For a definitive version of this work, please refer
to the published source. Please note that access to the published version might require a
subscription.
Chalmers Publication Library (CPL) offers the possibility of retrieving research publications produced at Chalmers
University of Technology. It covers all types of publications: articles, dissertations, licentiate theses, masters theses,
conference papers, reports etc. Since 2006 it is the official tool for Chalmers official publication statistics. To ensure that
Chalmers research results are disseminated as widely as possible, an Open Access Policy has been adopted.
The CPL service is administrated and maintained by Chalmers Library.
(article starts on next page)
OPEN
ORIGINAL ARTICLE
A mega-analysis of ﬁxed-dose trials reveals dose-dependency
and a rapid onset of action for the antidepressant effect of three
selective serotonin reuptake inhibitors
F Hieronymus1, S Nilsson2 and E Eriksson1
The possible dose-dependency for the antidepressant effect of selective serotonin reuptake inhibitors (SSRIs) remains controversial.
We believe we have conducted the ﬁrst comprehensive patient-level mega-analysis exploring this issue, one incentive being to
address the possibility that inclusion of low-dose arms in previous meta-analyses may have caused an underestimation of the
efﬁcacy of these drugs. All company-sponsored, acute-phase, placebo-controlled, ﬁxed-dose trials using the Hamilton Depression
Rating Scale (HDRS) and conducted to evaluate the effect of citalopram, paroxetine or sertraline in adult major depression were
included (11 trials, n= 2859 patients). The single-item depressed mood, which has proven a more sensitive measure to detect an
antidepressant signal than the sum score of all HDRS items, was designated the primary effect parameter. Doses below or at the
lower end of the usually recommended dose range (citalopram: 10–20 mg, paroxetine: 10 mg; sertraline: 50 mg) were superior to
placebo but inferior to higher doses, hence conﬁrming a dose-dependency to be at hand. In contrast, among doses above these,
there was no indication of a dose–response relationship. The effect size (ES) after exclusion of suboptimal doses was of a more
respectable magnitude (0.5) than that usually attributed to the antidepressant effect of the SSRIs. In conclusion, the observation
that low doses are less effective than higher ones challenges the oft-cited view that the effect of the SSRIs is not dose-dependent
and hence not caused by a speciﬁc, pharmacological antidepressant action. Moreover, we suggest that inclusion of suboptimal
doses in previous meta-analyses has led to an underestimation of the efﬁcacy of these drugs.
Translational Psychiatry (2016) 6, e834; doi:10.1038/tp.2016.104; published online 7 June 2016
INTRODUCTION
Although selective serotonin reuptake inhibitors (SSRIs) have since
long been extensively used for the treatment of depression, it
remains controversial whether they display a dose–response
relationship. Thus, while a number of individual studies and meta-
analyses do suggest a dose-dependency to be at hand,1–7 several
authors systematically reviewing the outcomes of individual
studies have concluded that high doses are no more effective
than low,1–3 the dose–response curve often being described as
ﬂat. This possible lack of a dose–response relationship for the
SSRIs has recently gained renewed interest, as it has been put
forward as an argument for the claim that they are devoid of
speciﬁc, pharmacological antidepressant actions.8–10 To clarify
whether the antidepressant effect of the SSRIs is indeed unrelated
to dose has, for this reason, emerged as a task of considerable
theoretical importance.
This matter has obvious bearing on clinical practice. If high
doses are no more effective than the lowest recommended one,
the commonly applied dose escalation strategy in cases of
non-response may be counterproductive by needlessly increasing
the burden of side effects. In addition, if the effect of an SSRI
is an all-or-nothing phenomenon, the SSRIs should perhaps
preferably be prescribed at doses even lower than those currently
recommended. On the other hand, if these drugs do display dose-
dependency, the widespread assumption that they do not may
prompt clinicians to use suboptimal dosage.11 Illustrating the
unfortunate ambiguity of the current evidence on this matter, two
British guidelines state that no dose-dependency has been
established,4,5 whereas the American Psychiatric Association
recommends dose escalation in cases of non-response.6
The effect sizes (ES) for comparisons of SSRIs versus placebo in
drug company-sponsored trials using the conventional measure of
efﬁcacy are usually small (0.3–0.4).12 Regardless of whether such
modest outcomes are true reﬂections of a relatively poor
efﬁcacy,8,13,14 or whether they are artiﬁcially low because of the
methodological shortcomings marring company-sponsored
trials,15–17 they justify the conclusion that detecting signiﬁcant
differences between two doses that are both superior to placebo
would require a large number of subjects.3,15 Most individual
dose–response studies being marred by too low statistical power
to detect differences between doses might, hence, partly explain
why previous systematic reviews have reached the conclusion that
no dose–response relationship is at hand.1–3 Supporting this
possibility, three7,18,19 out of four8 meta-analyses addressing this
issue do, in fact, suggest the antidepressant effect of the SSRIs to
be dose-dependent.
One aspect that may have hampered the attempts to reveal
differences between doses in SSRI trials is the common use of the
reduction in the sum rating of the 17 items on the Hamilton
Depression Rating Scale (HDRS-17-sum) as effect parameter.20 As
some of the symptoms included in this multidimensional
1Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden and 2Institute of Mathematical Sciences, Chalmers University of
Technology, Gothenburg, Sweden. Correspondence: Professor E Eriksson, Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, PO Box 432,
Gothenburg SE 405 30, Sweden.
E-mail: elias.eriksson@neuro.gu.se
Received 25 April 2016; accepted 25 April 2016
Citation: Transl Psychiatry (2016) 6, e834; doi:10.1038/tp.2016.104
www.nature.com/tp
inventory are absent in many depressed patients already at
baseline, and some are common also in non-depressed subjects
and/or are frequent side effects of SSRIs, the feasibility of this
measure for detecting differences between groups in SSRI trials
has been frequently questioned.16,17,20,21 Accordingly, we recently
showed the likelihood of detecting an antidepressant signal in
placebo-controlled trials to be far higher when using one key item
from this scale, depressed mood (rated 0–4), rather than HDRS-17-
sum, as a measure.17
In order to clarify the question of a possible dose-dependency
for the SSRIs across the entire possible dose range, that is, from
doses lower than those recommended to the highest that have
been tested in ﬁxed-dose studies, we have conducted a post hoc
patient-level mega-analysis using depressed mood as primary and
HDRS-17-sum as secondary effect parameters. To avoid any bias in
the selection of studies, and to obtain sufﬁcient statistical power,
all company-sponsored ﬁxed-dose, placebo-controlled trials con-
ducted for three of the ﬁrst-generation SSRIs, citalopram,
paroxetine and sertraline, were included.
MATERIALS AND METHODS
Data acquisition
Patient-level data from all drug company-sponsored ﬁxed-dose, placebo-
controlled trials regarding the treatment of depression in adults that have
been conducted for citalopram, escitalopram, paroxetine, ﬂuoxetine and
sertraline were requested from GlaxoSmithKline (GSK, Brentford, UK;
paroxetine), Lilly (Indianapolis, IN, USA; ﬂuoxetine), Lundbeck (Valby,
Denmark; citalopram and escitalopram), Actavis (Parsippany-Troy Hills, NJ,
USA; escitalopram) and Pﬁzer (New York, NY, USA; sertraline). Data for
ﬂuvoxamine were not requested, as it was deemed sufﬁcient to include
those SSRIs that are currently commonly prescribed for the treatment of
depression. Whereas the manufacturers of citalopram, paroxetine and
sertraline sent us the requested data, individual item data on ﬂuoxetine
were unfortunately not available in an electronic format and could hence
not be delivered. Although we did obtain patient-level data also from the
escitalopram trials conducted by Lundbeck, these were not relevant for
this analysis since only one dose (10 mg) had been tested using a ﬁxed-
dose design. We have tried to obtain patient-level data from trials
sponsored by the other company involved in the clinical trial program for
escitalopram, that is, Forest, but the company that has since then acquired
Forest, that is, Actavis, has unfortunately not been able to submit the
requested information in electronic format. We conﬁrmed that we had
access to all pertinent studies regarding citalopram, paroxetine and
sertraline by examining the Food and Drug Administration-approval
packages for the relevant drugs.17
Only two sertraline studies (PZ/101 and PZ/310) comprised a 400-mg
dose, and these lasted for 4 weeks only; hence, no efﬁcacy measures were
available for this dosage beyond week 4. The polymeric matrix used in
paroxetine-controlled-release (CR) releases ~ 80% of the active
compound;22 the company hence used the doses 12.5 and 25 mg of
paroxetine CR, assuming that they should correspond to 10 and 20 mg of
paroxetine immediate-release. We have similarly assumed that patients
medicating with paroxetine CR 12.5 or 25 mg per day received a daily
paroxetine dose of 10 and 20 mg, respectively. None of the studies
included a comparator SSRI given in a ﬁxed-dose manner; therefore, for
each study only data regarding one compound were obtained.
Statistics
Recently, mixed models for repeated measurements have replaced last-
observation-carried-forward-based analysis of covariance as the preferred
methodology for antidepressant trials.23 For all analyses on ordinal
outcome measures, we, hence, implemented a linear mixed model using
the PROC MIXED procedure in SAS version 9.4 (SAS Institute, Cary, NC,
USA). The basic model included change score for the relevant measure
(depressed mood or HDRS-17-sum) as the dependent variable, time (week)
and trial as ﬁxed factors, and baseline rating on the outcome parameter as
covariate. An unstructured (co)variance structure was used to model
within-patient errors. Denominator degrees of freedom were estimated
using the Kenward–Roger approximation. ES (Cohen’s d) were calculated
by dividing the least-squares means differences for the relevant contrast
by the root of the variance for the corresponding time point taken from
the covariance matrix. For analyses spanning multiple weeks, the between-
treatment contrast(s) at the last evaluation (usually week 6) were
considered primary outcome. P-values are reported without adjustment
for multiple comparisons; all signiﬁcance tests reported are two-sided.
Whereas the depressed mood item of the Hamilton Depression Rating Scale
was regarded as the primary effect parameter, most analyses were
repeated using HDRS-17-sum as an alternative measure.
To shed light on the possible relationship between dose and effect for
each antidepressant, we ﬁrst modeled dose as a categorical predictor for
all drugs separately and including only the placebo cases from the trials in
which the drug in question had been evaluated. Here the basic model was
extended by including a ﬁxed factor for dose and the interaction between
dose and time. For these analyses, only depressed mood was used as effect
parameter.
We then conducted a pooled dose–response analysis comprising all
three SSRIs and using both depressed mood and HDRS-17-sum as effect
parameters. As the issue of dose-equivalency between different SSRIs
remains unsettled,18 visual inspection of the results of the drug-speciﬁc
analyses was used to produce an optimal-dose and a low-dose group. The
basic model was extended by including a ﬁxed factor for dose group
(placebo, low-dose and optimal-dose) and the interaction between dose
group and time. Acknowledging the exploratory nature of the pooling
procedure, we also re-ran this analysis including only the lowest and
highest doses for each compound. For sertraline, the 200-mg dose was
used for this purpose as the highest dose (400 mg) had been evaluated in
4-week studies only.
We also modeled dose as a linear covariate for all SSRI cases pooled, but
excluding placebo-treated patients, using both depressed mood and
HDRS-17-sum as outcome measures; here the interaction between time
and the linearized dose covariate was added to the basic model. Doses
were normalized so that the lowest dose for each drug was anchored at
zero and the highest at one, doses in between being linear interpolations
between these two.
As the pooled assessment comprising all three SSRIs was focused on
the possible difference between doses at the lower end of the dose–
response curves on the one hand and all higher doses on the other, but
not within the dose range that may be described as medium to high, we
also conducted a pooled analysis where only doses within the latter range
(that is, citalopram ⩾ 40 mg, paroxetine ⩾ 20 mg and sertraline ⩾ 100 mg)
were included. Again, dose was treated as a linear covariate and
normalized so that the lowest included dose was anchored at zero and
the highest at one, doses in between being linear interpolations between
these two.
Finally, we modeled the likelihood of achieving response or remission in
the pooled population again divided into the low-dose and optimal-dose
groups. For depressed mood, response was deﬁned as a lower rating than at
baseline and remission as a rating of zero. For HDRS-17-sum, response was
deﬁned as a ⩾ 50% decrease and remission as a score of ⩽ 7.4–6 The
models were ﬁtted using the PROC GLIMMIX procedure and included time
(week), dose group, trial and the interaction between time and dose group
as ﬁxed factors, and the baseline ratings of depressed mood or HDRS-17-
sum, respectively, as covariate. All time points were included in the model
but only the week 6 results are reported. The model used a binary
distribution with a logit link, the Kenward–Roger approximation was
applied to estimate denominator degrees of freedom and an unstructured
(co)variance structure was used to model the within-patient errors.
Ethics
The Regional Ethical Review Board reviewed the study protocol and issued
an advisory opinion stating no objection.
RESULTS
The data set consists of 2859 patients with valid baseline data and
at least one post-baseline measurement (Table 1). Of these, 600
received citalopram (10–60 mg), 1043 paroxetine (10–40 mg), 481
sertraline (50–400 mg) and 735 placebo.
Figure 1 shows mean changes, effect sizes and levels of
signiﬁcance for all individual doses of the three drugs when using
change in depressed mood as outcome parameter. In the
paroxetine studies, no evaluations had been made at week 5. All
drugs and doses showed signiﬁcant superiority over placebo at
some point of observation; of particular note is that citalopram
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(40 mg) and paroxetine (10, 20 and 40 mg) separated signiﬁcantly
from placebo already after 1 week. Differences between doses
only occasionally reached statistical signiﬁcance.
Inspection of the dose curves for citalopram suggests the effect
of 10 mg to be similar to that of 20 mg, but both these doses
display lower efﬁcacy than 40 and 60 mg; for the pooled analysis,
10 and 20 mg were, hence, classiﬁed as low doses, whereas 40 and
60 mg were regarded as optimal doses. For paroxetine, the largest
difference was seen between the 10 mg group on the one hand
and the 20, 30 and 40 mg groups on the other; hence, 10 mg was
the only dose classiﬁed as low. For sertraline there was no
apparent difference between 100 , 200 and 400 mg, whereas
50 mg produced a lower response; consequently, 50 mg was
designated as low and the other doses as optimal.
Figure 2 displays levels of signiﬁcance, ES and the mean
changes in HDRS-17-sum (Figure 2a) and depressed mood
(Figure 2b) for the pooled dose groups. With respect to reduction
in depressed mood, both dose groups outperformed placebo after
1 week, optimal-dose outperforming low-dose after 5 weeks. With
respect to reduction in HDRS-17-sum, both doses separated
signiﬁcantly from placebo after 2–3 weeks of treatment,
optimal-dose outperforming low-dose after 6 weeks.
Figure 3 is equivalent to Figure 2 but displays the results of the
sensitivity analysis including only the lowest and highest doses for
each compound. With respect to reduction in HDRS-17-sum, both
dose groups separated signiﬁcantly from placebo after 3–4 weeks
of treatment; however, the difference between the lowest and the
highest doses was never signiﬁcant (week 6: P= 0.08). With respect
to reduction in depressed mood, both dose groups separated
signiﬁcantly from placebo after 1 week and from each other after
4 weeks and onwards.
For the overall linearized dose analysis using depressed mood as
the effect parameter, a signiﬁcant effect of dose was found at
week 3 (β=− 0.15 (0.08), t=− 2.05, P= 0.04), 4 (β=− 0.21 (0.08),
t=− 2.67, P= 0.008), 5 (β=− 0.25 (0.10), t=− 2.43, P= 0.02) and 6
(β=− 0.31 (0.09), t=− 3.55, Po0.001). When HDRS-17-sum was
instead used as the measure of response, a signiﬁcant dose effect
was observed at week 6 (β=− 1.14 (0.57), t=− 1.98, P= 0.047). For
the subgroup analysis within the optimal-dose group there was,
on the other hand, no signiﬁcant effect of dose at any point of
assessment either with respect to depressed mood (week 6:
β=− 0.09 (0.15), t=− 0.64, P= 0.5) or with respect to HDRS-17-sum
(week 6: β= 1.05 (0.96), t= 1.10, P= 0.3).
Table 2 details the analyses of categorical outcomes at week 6.
Optimal-dose was signiﬁcantly superior to low-dose both with
respect to the percentage of subjects showing response using the
depressed mood item and with respect to the percentage of
subjects displaying no depressed mood at week 6. Similar results
were found using HDRS-17-sum as the measure. For all measures,
both low-dose and optimal-dose SSRI outperformed placebo.
DISCUSSION
This study differs from previous attempts to disclose a possible
dose–response relationship for the antidepressant effect of SSRIs
in three regards: by including a more sensitive effect parameter
(the depressed mood item) than the usual one (HDRS-17-sum),17 by
using a statistical method (mixed models for repeated measure-
ment) more appropriate for handling missing data than previous
techniques23 and by being based on patient-level data from all
relevant trials of the three study drugs, the latter premise
precluding the inﬂuence of publication bias and rendering the
studied population unusually large for a patient-based analysis. As
a result, we made three observations, partly challenging the
conventional wisdom. First, we could refute the assumption of a
ﬂat dose–response curve; thus, whereas doses below or at the
lower end of the dose range usually recommended were superior
to placebo, they were inferior to higher doses. Second, the ES forT
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Figure 1. Trajectories of change, effect sizes (ES) and levels of signiﬁcance for individual drugs (a, citalopram; b, paroxetine; c, sertraline) and
doses. Shown are the mean reductions in depressed mood. ES and levels of signiﬁcance for all comparisons versus placebo (P) are displayed in
the lower parts of the graph: *Po0.05, **Po0.01, ***Po0.001. Between-dose differences that are statistically signiﬁcant are indicated with
the superscripted letters a–f. a60 and 20 mg citalopram (ES: 0.34, P= 0.01), b40 and 20 mg citalopram (ES: 0.29, P= 0.02), c40 and 20 mg
citalopram (ES: 0.26, P= 0.03), d60 and 20 mg citalopram (ES: 0.41, P= 0.003), e20 and 10 mg paroxetine (ES: 0.27, P= 0.005) and f100 and 50 mg
sertraline (ES: 0.35, P= 0.04).
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Figure 2. Trajectories of change, effect sizes (ES) and levels of signiﬁcance for the pooled analyses comprising all subjects. Shown are the
mean reductions on the 17 item Hamilton Depression Rating Scale (HDRS-17-sum) (panel a) and depressed mood (panel b). ES and levels of
signiﬁcance for all comparisons between treatment groups are displayed in the lower parts of the graph (L, low-dose; O, optimal-dose;
P, placebo; v, versus): *Po0.05, **Po0.01, ***Po0.001.
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the difference between optimal doses of SSRIs and placebo
with respect to reduction in depressed mood was considerably
larger than that usually attributed to these drugs. And third, SSRIs
outperformed placebo already after 1 week of treatment.
In spite of the fact that antidepressant trials are marred by
methodological shortcomings that we could not adjust for in this
analysis, and most of which are likely to make the difference
between two treatments, appear smaller than it actually is;15–17
the ES for the difference between placebo and optimal-dose
SSRI with respect to reduction in depressed mood was 0.5–0.6
(Figures 2 and 3), that is, well on par with that reported for many
well-established treatments in somatic medicine.24 We suggest
that previous assessments of the usefulness of the SSRIs8 have
understated their efﬁcacy, both by being based on a questionable
measure of response and also by including patients treated with
suboptimal doses. In addition, whereas the alleged lack of a dose–
response relationship for the SSRIs has been used as an argument
for the claim that these drugs are devoid of speciﬁc antidepres-
sant properties,8–10 the ﬁnding that optimal doses are indeed
superior to lower though effective ones refutes this assumption.
As many different symptoms contribute to the distress
associated with depression, important aspects of a given
treatment may be overlooked when measuring severity by
assessing one symptom only; regulatory authorities hence have
0 2 4 6
-16
-12
-8
-4
0
Week
M
ea
n 
D
iff
er
en
ce
 +
 S
EM
 (H
D
R
S-
17
)
0 ns
-0.07 ns
-0.07 ns
0.09 ns
0.05 ns
-0.04 ns
0.18**
0.13 ns
-0.05 ns
0.17**
0.23**
0.06 ns
0.19*
0.26**
0.07 ns
0.20**
0.34***
0.15 ns
PvL:
PvH:
LvH:
Placebo (n=735)
Lowest-dose (n=674)
Highest-dose (n=333)
0 2 4 6
-2.0
-1.5
-1.0
-0.5
0.0
Week
M
ea
n 
D
iff
er
en
ce
 +
 S
EM
 (D
ep
re
ss
ed
m
oo
d)
0.14*
0.23**
0.10 ns
0.18**
0.23**
0.04 ns
0.28***
0.34***
0.06 ns
0.28***
0.45***
0.17*
0.25**
0.48***
0.23*
0.31***
0.57***
0.26**
PvL:
PvH:
LvH:
Placebo (n=735)
Lowest-dose (n=674)
Highest-dose (n=333)
a b
Figure 3. Trajectories of change, effect sizes (ES) and levels of signiﬁcance for the sensitivity analyses (lowest versus highest doses). Shown are
the mean reductions on the 17 item Hamilton Depression Rating Scale (HDRS-17-sum) (panel a) and depressed mood (panel b). ES and levels of
signiﬁcance for all comparisons between treatment groups are displayed in the lower parts of the graph (H, highest dose; L, lowest dose; P,
placebo; v, versus): *Po0.05, **Po0.01, ***Po0.001.
Table 2. Categorical outcomes at week 6
Group Response Remission
% Odds ratio (CI) P % Odds ratio (CI) P
HDRS-17
Placebo versus low-dose 44.7 51.6 1.32 (1.01–1.72) 0.04 24.8 33.5 1.53 (1.13–2.06) 0.005
Placebo versus optimal-dose 44.7 61.6 1.98 (1.53–2.57) o0.001 24.8 39.9 2.01 (1.51–2.68) o0.001
Low-dose versus optimal-dose 51.6 61.6 1.51 (1.19–1.90) o0.001 33.5 39.9 1.32 (1.03–1.68) 0.03
Depressed mood
Placebo versus low-dose 70.5 78.8 1.56 (1.15–2.13) 0.005 15.6 27.9 2.09 (1.47–2.96) o0.001
Placebo versus optimal-dose 70.5 85.9 2.56 (1.86–3.50) o0.001 15.6 35.0 2.91 (2.08–4.06) o0.001
Low-dose versus optimal-dose 78.8 85.9 1.64 (1.21–2.22) 0.002 27.9 35.0 1.39 (1.08–1.80) 0.01
Abbreviation: CI, conﬁdence interval; HDRS-17, Hamilton Depression Rating Scale 17-item version.
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required the use of multi-item scales, such as the HDRS, for
evaluating efﬁcacy. In addition, supporting this stance, it has been
demonstrated that single-item measures usually result in a lower
inter-rating reliability than multi-item rating scales.20 On the other
hand, the use of a measure of efﬁcacy composed by the sum score
of 17 symptoms, many of which are often not present at baseline,
and many of which may be present at end point also in patients
who have recovered, is bound to result in suboptimal sensitivity
by enhancing variability, hence making the tested compound
appear less effective than it actually is. In line with this, we found
differences between doses (and between active medication and
placebo) to be larger when replacing the conventional effect
parameter, that is, the HDRS-17-sum, with a single symptom that is
present in most subjects at baseline and of obvious clinical
relevance, that is, depressed mood. This observation is well in line
with our previous report (partly based on the same data set)
showing that the depressed mood item from the HDRS is a
considerably more sensitive measure than the HDRS-17-sum for
detecting an antidepressant signal.17 The pros and cons of single-
item assessments versus multi-item assessments have been
elaborated upon elsewhere.17,20,21
The ES at end point for the differences between optimal-dose
and low-dose SSRIs were 0.21 (depressed mood) and 0.17
(HDRS-17-sum), respectively. ES of these moderate magnitudes
for the inﬂuence of dose are compatible with the assumption that
the discrepancy between those previous meta-analyses that have
obtained support for a dose–response relationship7,18,19 and
the systematic reviews that have not1–3 may partly be a matter
of statistical power.
A superiority of optimal-dose over low-dose could be explained
either by a lower number of non-responders among those given
an optimal dose or by a larger symptom reduction in responders
given an optimal dose than in responders given a low dose. The
analyses of categorical outcomes suggest both alternatives to be
relevant; optimal doses hence were associated both with fewer
subjects not reporting any reduction in depressed mood and with
more patients reporting no depressed mood at the week 6 end
point (Table 2). Of note, and again underlining the beneﬁt of SSRIs,
is that more than 1/3 of patients in the optimal-dose group, but
less than 1/6 of those on placebo, reported absence of depressed
mood at the week 6 end point.
Beyond the conclusion that doses of SSRIs below or at the lower
end of the dose range usually recommended are inferior to higher
doses, we caution against using our results for dosing recom-
mendations, the number of patients given each dose of each
compound being relatively low. In addition, it should be noted
that the proportion of subjects given high and low doses differ
between drugs; subjects given high doses of paroxetine were thus
relatively few. Moreover, with respect to sertraline, only one of the
three trials including the 50 mg dose lasted for 6 weeks. Taking
these caveats into consideration, inspection of the data regarding
the individual drugs (Figure 1), however, suggests that the effect
of sertraline is likely to be augmented by dose escalation from the
lowest recommended dose (50 mg), which is at odds with some
previous reports.25,26 With respect to citalopram, a dose of 20 mg,
which is a recommended dose in some European countries, such
as the United Kingdom, but lower than the lowest recommended
dose in the United States (40 mg), appeared less effective than
doses of 40 mg and above; of note is however that citalopram
doses higher than 40 mg should be avoided because of a possible
risk for QTc prolongation.27 Paroxetine seems to display its
maximum efﬁcacy at the minimal recommended dose (20 mg),
which is in line with a report suggesting that higher doses of this
compound cause no further increase in serotonin transporter
occupancy.28
Whereas the pooled analyses revealed clear-cut differences
between low (yet not ineffective) doses and higher ones,
inspection of the dose–response curves for the individual drugs
suggests these to plateau at 20 mg for paroxetine, 40 mg for
citalopram and 100 mg for sertraline. These doses are all
within the ranges generally recommended for the treatment of
depression, e.g., by the FDA (sertraline: 50–200 mg, citalopram:
40 mg, paroxetine: 20-50 mg); however, for citalopram and
sertraline, but not for paroxetine, they are higher than the World
Health Organization’s deﬁned daily dose for moderately severe
depression (sertraline: 50 mg, citalopram: 20 mg, paroxetine:
20 mg).
The assumption that doses above 20 mg for paroxetine, 40 mg
for citalopram and 100 mg for sertraline are not associated with a
further increase in antidepressant effect gains support from the
fact that the linear analysis conducted within the medium-to-high
dose range yielded no signiﬁcant effect of dose. On the other
hand, these results contrast to those of a recent meta-analysis
suggesting very high doses (sertraline: 240–300 mg, citalopram:
60–75 mg, paroxetine: 40–50 mg) to be superior to medium
ones.7 Whereas our mega-analysis is based on ﬁxed-dose studies
only, this meta-analysis was, to a considerable extent, based on
ﬂexible-dose studies that appear to have been categorized as if all
patients had actually been given the highest dose allowed; as the
reported median dose in ﬂexible-dose studies usually is consider-
ably lower than the maximal dose, this assumption may however
be questioned. Further, as the highest doses allowed in ﬂexible-
dose studies are often higher than the highest doses tested in
ﬁxed-dose studies, it is not unlikely that the apparent superiority
of very high doses suggested by Jakubovski and co-workers,29
doses that have rarely been tested in ﬁxed-dose studies, might in
fact be an effect of study design (ﬂexible dosage) rather than of
the dose itself. Other differences between the two studies are that
the present analysis is based on patient-level data and, for the
three studied drugs, comprises all company-sponsored trials,
including the non-published ones, hence avoiding the risk of
publication bias.
The observation of a signiﬁcant difference between active drug
and placebo in reducing depressed mood (but not HDRS-17-sum) as
early as after 1 week is in line with previous data regarding
another SSRI, ﬂuvoxamine,30 but contrasts to the common view
that SSRIs require 2 weeks or more to exert any antidepressant
effect.31 Although the symptom reduction observed after 1 week
is small, and of questionable clinical relevance, it is of considerable
theoretical interest as it casts doubt on the assumption that a
likely mechanism of action of the SSRIs is one that requires
prolonged administration, such as, for example, the formation of
new nerve cells.31 Instead, our data suggest the antidepressant
effect to be the result of a process that, although gradual and
sluggish, is manifested already within the ﬁrst week of treatment,
a view gaining support also by studies addressing the inﬂuence of
SSRIs on emotional processing.32 In this context, it should be
noted that there are, in fact, a number of previous studies
suggesting SSRIs to outperform placebo within a week also with
respect to reducing HDRS-17-sum.33,34
This study has certain limitations. One such is that not all SSRIs
were included for reasons presented above. This drawback,
however, does not preclude the major conclusions of the study,
that is, that the antidepressant effect of SSRIs, in contrast to what
has been claimed by others, may display a dose–response
relationship, and that at least some SSRIs outperform placebo
already after 1 week of treatment. A second limitation is that we
had no possibility to relate serum levels of the given compound
with response as such analyses unfortunately are seldom included
in this kind of company-sponsored trials. It should also be noted
that the ﬁxed-dose design of the included trials does not allow for
any deﬁnite conclusion regarding the possible beneﬁt of
increasing the dose in a subgroup of patients who have failed
to respond to a given dose. Finally, for the individual patient, the
possible beneﬁt of giving a higher dose must, needless to say, be
weighed against the possible drawback of a greater side effect
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burden; while the aim of this study was to shed light on the
possible association between dose and efﬁcacy, our analyses do
not provide any information regarding the tolerability of higher
doses as compared to lower.
To summarize, the present study permits three conclusions.
First, the antidepressant effect of the SSRIs is characterized by a
dose–response relationship, low doses being superior to placebo
but inferior to the optimal ones; above these low doses there
was however no support for the highest doses being the most
effective. Second, the ES for the difference between placebo and
an optimal SSRI dose is of a more respectable magnitude than has
usually been attributed to the antidepressant effect of the SSRIs,
hence casting doubt on the claim that these drugs are devoid of
clinically relevant antidepressant properties. Third, a small but
signiﬁcant superiority of SSRIs over placebo in reducing depressed
mood is observed already after 1 week of treatment.
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